Search results
Results from the WOW.Com Content Network
Dapagliflozin, sold under the brand names Farxiga (US) and Forxiga (EU) among others, is a medication used to treat type 2 diabetes. [ 6 ] [ 7 ] [ 10 ] It is also used to treat adults with heart failure and chronic kidney disease .
The program is designed to help people navigate through what is likely the most challenging time of their life.
Dapagliflozin, (brand name Forxiga), was approved by the EU in 2012, the first SGLT2 inhibitor approved anywhere. [28] It was approved for use in the United States under the brand name Farxiga in January 2014. [29] Empagliflozin, approved in the United States in August 2014, under the brand name Jardiance by Boehringer Ingelheim. [30]
Through this free service, specialists and master's-level clinicians offer confidential support and information to people living with dementia, caregivers, families and the public. [4] The Association also has free online tools to help people find answers, local resources and support.
CaringBridge allows patients, caregivers, families, and friends to exchange information about a patient's medical condition on an ongoing basis. [3] The websites are designed to become conduits between patients, their families, friends, neighbors, and colleagues. [4]
Design, Dignity, Dementia: dementia-related design and the built environment Collates the progress which has been made in dementia-related design to date, including best practice from pioneers and innovators across multiple environments including in home/domestic settings, day and residential care, hospitals and public buildings and spaces. [38]
To lessen the risk of developing ketoacidosis (a serious condition in which the body produces high levels of blood acids called ketones) after surgery, the FDA has approved changes to the prescribing information for SGLT2 inhibitor diabetes medicines to recommend they be stopped temporarily before scheduled surgery.
Regarding incidence, cohort longitudinal studies (studies where a disease-free population is followed over the years) provide rates between 10 and 15 per thousand person-years for all dementias and 5–8 for AD, [236] [237] which means that half of new dementia cases each year are Alzheimer's disease. Advancing age is a primary risk factor for ...